Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease |
| |
Authors: | Auerbach M Al Talib K |
| |
Affiliation: | Auerbach Hematology and Oncology, Baltimore, Maryland 21237, USA. mauerbachmd@aol.com |
| |
Abstract: | Serious adverse events that occur with the administration of iron dextran are due to the high molecular weight preparations. Conclusions that iron sucrose and ferric gluconate are safer than iron dextran may be premature. Published literature comparing safety profiles of available parenteral iron products is reviewed. Administration of iron salts to pre-dialysis patients with chronic kidney disease may not be optimal. We recommend the total dose infusion of low molecular weight iron dextran as an option for iron replacement. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|